Re: Roberti R, Iannone LF, Palleria C, et al. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Curr Med Res Opin. 2020. DOI:10.1080/03007995.2020.1786681
- 5 August 2020
- journal article
- letter
- Published by Taylor & Francis Ltd in Current Medical Research and Opinion
- Vol. 36 (10), 1627-1628
- https://doi.org/10.1080/03007995.2020.1799775
Abstract
RE: Roberti R, Iannone LF, Palleria C, et al. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Curr Med Res Opin. 2020; DOI: https://doi.org/10.1080/03007995.2020.1786681. Current Medical Research and Opinion. Accepted 20 July 2020.Keywords
This publication has 6 references indexed in Scilit:
- Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern ItalyCurrent Medical Research and Opinion, 2020
- P330 Inflammatory Bowel Disease (IBD) patients frequently report adverse drug reactions during biologic therapy: A multicentre, prospective, patient-reported pharmacovigilance monitoring systemJournal of Crohn's and Colitis, 2020
- Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel DiseaseJAMA, 2017
- Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment RegistryJournal of the American Academy of Dermatology, 2017
- Risk of Serious Infection With Biologic and Systemic Treatment of PsoriasisJAMA Dermatology, 2015
- Alleged isotretinoin-associated inflammatory bowel disease: Disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting SystemJournal of the American Academy of Dermatology, 2013